Cargando…

Intranasal esketamine + Intensive CBT: a 12 months follow-up of two complicated cases of Treatment Resistant Depression at high suicidal risk

INTRODUCTION: Treatment Resistant Depression (TRD) is a complex, heterogeneous and multifactorial clinical condition that affects patients’ quality of life, their psychosocial functioning as well as suicidal risk. Intranasal esketamine is a new add-on treatment specifically approved for TRD. OBJECTI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martiadis, V., Raffone, F., Cerlino, R., Testa, S., Russo, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479075/ http://dx.doi.org/10.1192/j.eurpsy.2023.1792

Ejemplares similares

Intranasal Esketamine + CBT: a 6 months follow-up of a resistant depression complicated case
por: Martiadis, V., et al.
Publicado: (2022)

Metacognition, emotional dysregulation, psychosocial functioning and subjective well-being after 6 months of CBT treatment in pharmacologically stabilized schizophrenic patients
por: Raffone, F., et al.
Publicado: (2023)

The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
por: Pepe, Maria, et al.
Publicado: (2023)

Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
por: Wang, Sheng-Min, et al.
Publicado: (2021)

Intranasal esketamine and the dawn of precision psychiatry
por: Watts, Devon, et al.
Publicado: (2021)

Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
por: Carter, Maximilian, et al.
Publicado: (2022)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
por: Hernandez Huerta, D., et al.
Publicado: (2022)

Intranasal Esketamine and Current Suicidal Ideation With Intent in Major Depression Disorder: Beat the Clock, Save a Life, Start a Strategy
por: Pompili, Maurizio
Publicado: (2020)

Intranasal Esketamine administration in catatonia: a case report.
por: Romay, J., et al.
Publicado: (2023)

Dissociating the Clinical Role and Economic Value of Intranasal Esketamine
por: Dadiomov, David
Publicado: (2020)

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review
por: Sapkota, Alisha, et al.
Publicado: (2021)

Intranasal esketamine as therapeutic option: a case report of an adolescent with treatment resistant depression
por: Skala, Katrin, et al.
Publicado: (2023)

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases
por: Mercado-Rodríguez, A., et al.
Publicado: (2023)

The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder
por: Dijkstra, Francis M, et al.
Publicado: (2022)

Brexpiprazole augmentation in a clozapine-resistant young schizophrenic patient: a successful case report.
por: Martiadis, V., et al.
Publicado: (2023)

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
por: Capuzzi, Enrico, et al.
Publicado: (2021)

Intranasal esketamine use in bipolar disorder: A case report
por: Skriptshak, Courtney, et al.
Publicado: (2021)

The antidepressant effect and safety of non-intranasal esketamine: A systematic review
por: Smith-Apeldoorn, Sanne Y, et al.
Publicado: (2022)

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
por: Fu, Dong-Jing, et al.
Publicado: (2023)

Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report
por: Olivola, Miriam, et al.
Publicado: (2022)

Median effective dose of esketamine for intranasal premedication in children with congenital heart disease
por: Huang, Jiajia, et al.
Publicado: (2023)

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis
por: Chen, Cheng-Chuan, et al.
Publicado: (2023)

A Comparison of Intranasal Dexmedetomidine, Esketamine or a Dexmedetomidine-Esketamine Combination for Induction of Anaesthesia in Children: A Randomized Controlled Double-Blind Trial
por: Lu, Xinlei, et al.
Publicado: (2022)

Cariprazine add-on for resistant bipolar depression: preliminary results from an italian real-world experience
por: Martiadis, V., et al.
Publicado: (2023)

The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis
por: Floriano, Idevaldo, et al.
Publicado: (2023)

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior
por: Canuso, Carla M., et al.
Publicado: (2021)

Urothelial toxicity of esketamine in the treatment of depression
por: Findeis, Hannelore, et al.
Publicado: (2020)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

Esketamine hydrochloride for treatment-resistant depression
Publicado: (2021)

Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa
por: Keeler, Johanna Louise, et al.
Publicado: (2023)

“Esketamine” in Borderline Personality Disorder: A Look Beyond Suicidality
por: Nandan, Neethu K, et al.
Publicado: (2022)

Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
por: Jollant, Fabrice, et al.
Publicado: (2023)

Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports
por: Marcatili, Matteo, et al.
Publicado: (2022)

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis: Letter in Response [Letter]
por: Manu, Lucian
Publicado: (2023)

CBT and medication in depression (Review)
por: Vasile, Cristian
Publicado: (2020)

CBT for Mild to Moderate Depression and Anxiety: A Guide to Low-Intensity Interventions
por: O'Shea, Chris
Publicado: (2016)

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis: Letter in Response [Response to Letter]
por: Chen, Cheng-Chuan, et al.
Publicado: (2023)

How effective are ketamine or esketamine in treatment-resistant depression?
por: Veluri, N., et al.
Publicado: (2021)

The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial
por: Liu, Haiyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6ivs0e499fcgroebrrqqr9d6fh